(415) 353-7171 (appts)

Box 1711, UCSF; San Francisco, CA 94143-1711

additional websites:

UCSF Physician Referral Directory

Harvard University, Cambridge, MA, AB, 1989-1993, Biology
UCLA School of Medicine, Los Angeles, CA, 1994-1996
University of Chicago, Pritzker School of Medicine, Chicago, IL MD, 1996-1999, Medicine
New York Presbyterian Hospital-Cornell, New York, NY, Internship/ residency, 1999-2002, Internal Medicine
University of California, San Francisco, San Francisco, CA, Fellowship, 2002-2005, Medicine (Hematology Oncology)
University of California, San Francisco, San Francisco, CA, Fellowship, 2005-2006, Medicine (Urologic Oncology)

Peer-reviewed publications

Bastos R, A Lin, M Enarson, B Burke. "Targeting and function in mRNA export of nuclear pore complex protein Nup153" Journal of Cell Biology 1996, 134(5):1141-1156

Wu MH, SL Smith, GH Danet, AM Lin, SF Williams, DN Liebowitz, ME Dolan. "Optimization conditions to enhance transfection of human CD34+ cells by electroporation" Bone Marrow Transplantation 2001, 27: 1201-1209

Lin AM, BI Rini, EJ Small. "Clinical trials in biochemically relapsed prostate cancer patients" BJU International 2006, 97(5):905-10.

Lin AM, BI Rini, V Weinberg, K Fong, CJ Ryan, JE Rosenberg, L Fong, EJ Small. "A phase II trial of imatinib mesylate in prostate cancer patients with biochemical relapse following definitive local therapy" BJU International 2006, Oct; 98(4):763-9.

Lin, AM, CJ Ryan, EJ Small. "Intermittent chemotherapy for metastatic hormone-refractory prostate cancer" Critical Reviews in Oncology and Hematology 2007 Mar ;61(3):243-54.

Lin, AM, BI Rini, M Kakefuda, V Weinberg, M Randall, CJ Ryan, JE Rosenberg, G Bubley, EJ Small. "A phase I trial of estramustine, docetaxel, and imatinib mesylate in hormone refractory prostate cancer patients" Clinical Genitourinary Cancer 2007 Jun; 5(5):323-8.

Ryan, CJ, AH Harzstark, J Rosenberg, A Lin, C Claros, ID Goldfine, JF KErner, EJ Small. "A pilot dose-escalation study of the effects of nordihydroguaracetic acid in hormone and prostate specific antigen levels in patients with relapsed prostate cancer" BJU International 2008, 101(4):436-9.

Ryan, CJ, V Weinberg, J Rosenberg, L Fong, A Lin, J Kim, EJ Small. "Phase II study of ketoconazole plus granulocyte-macrophage stimulating factor for prostate cancer: effect of extent of disease on outcome" J Urology 2007, Dec; 178(6):2372-6..

Non-peer reviewed publications:

"Screening tests for cancer: prostate cancer" The Medical Letter September 2005, 3(37):63-68

Lin AM, RM Hershberg, EJ Small. "Immunotherapy for prostate cancer using prostatic acid phosphatase (PAP) loaded antigen presenting cells" Urologic Oncology 2006 Sep-Oct;24(5):434-41.

Lin, AM, EJ Small, CJ Ryan. "A phase II trial of ketoconazole plus granulocyte macrophage-colony stimulating factor (GM-CSF) for androgen independent prostate cancer (AIPC)" Clinical Advances in Hematology and Oncology 2006, 4(4):16-19 (Supplement 9).

Ryan, CJ, AM Lin, EJ Small. "Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer" Urologic Oncology 2006, 24(3):250-3.

Lin, AM, EJ Small. "Prostate cancer update 2006" Current Opinion in Oncology 2007, 19(3): 229-233.

Lin, AM, EJ Small. "Asymptomatic hormone refractory prostate cancer" In press US Kidney and Urologic Disease 2007

Lin, AM, EJ Small. "Management of hormone refractory prostate cancer" In press Current Opinion in Supportive and Palliative Care 2007

Lin, AM, EJ Small. "Prostate cancer update 2007" Current Opinion in Oncology 2008, 20(3):294-9.

ABSTRACTS:

Wu MH, DN Liebowitz, KE Mikolajczak, AM Lin, SL Smith, SF Williams, ME Dolan. "Selective protection of bone marrow cells from alkylating agent toxicity" ISHAGE 1998 (poster presentation)

Wu, MH, DN Liebowitz, KE Mikolajczak, AM Lin, ME Dolan. "Sensitivity of mutant O6-alkylguanine-DNA alkyl transferases (AGT) to O6-benzylguanine (BG) and O6-benzyl-8-oxoguanine" Proceedings of the American Association of Cancer Research 1998, 39:517

Smith, SL, AM Lin, GH Danet, KE Mikolajczak, J Ng-Cashin, SF Williams, ME Dolan, DN Liebowitz. "Expansion of CD34 bright cells using Flt-3 ligand, stem-cell factor and thrombopoietin" ISHAGE 1998 (poster presentation)

Lin A, M Randall, B Rini, C Ryan, J Rosenberg, J Garcia, G Bubley, E Small. "The addition of imatinib mesylate to estramustine/docetaxel (E/D) for the treatment of hormone refractory prostate cancer patients: results of a phase I trial" Proceedings of American Society of Clinical Oncology 2004, 23:409, abstract #4617 (selected for poster presentation)

Lin AM, K Fong, V Weinberg, BI Rini, CJ Ryan, J Rosenberg, L Fong, C Haqq, EJ Small. "A phase II trial of imatinib mesylate in prostate cancer patients with biochemical relapse (BCR) after definitive local therapy" American Society of Clinical Oncology Multi-disciplinary Prostate Cancer Symposium 2005, abstract #258 (selected for poster presentation)

Lin AM, CJ Ryan, J Rosenberg, BI Rini, T Nguyen, V Weinberg, EJ Small. "A phase II trial of ketoconazole plus granulocyte macrophage-colony stimulating factor (GM-CSF) for androgen independent prostate cancer (AIPC)" American Society of Clinical Oncology 2005, abstract #4614 (selected for poster presentation)

Lin AM, CJ Ryan, J Rosenberg, BI Rini, T Nguyen, V Weinberg, EJ Small. "A phase II trial of ketoconazole plus granulocyte macrophage-colony stimulating factor (GM-CSF) for androgen independent prostate cancer (AIPC)" American Society of Clinical Oncology Multi-disciplinary Prostate Cancer Symposium 2006, abstract #219 (selected for poster presentation)

Lin, AM, JE Rosenberg, VK Weinberg, WK Kelly, MD Michaelson, M Hussain, G Wilding, ME Gross, EJ Small. "Clinical outcome of taxane-resistant hormone refractory prostate cancer patients treated with subsequent chemotherapy (ixabepilone or mitoxantrone/ prednisone)" Proceedings of the American Society of Oncology 2006, Part I. Vol 24, No. 18S (June 20 Supplement), abstract #4558 (selected for poster discussion)

Ryan, CJ, J Rosenberg, A Lin, L Ruttner, V Weinberg, E Small. "Outcome of patients with non-metastatic versus metastatic hormone refractory prostate cancer (HRPC) treated with second-line hormonal therapy consisting of ketoconazole (keto) plus granulocyte macrophage colony stimulating factor (GM-CSF)" Proceedings of the American Society of Clinical Oncology 2006, Part I. Vol 24, No. 18S (June 20 Supplement), abstract #4626 (selected for poster presentation)

Ryan, CJ, J Rosenberg, A Lin, J Valiente, J Kim, EJ Small. Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgen-independent prostate cancer (AiPC). Proceedings of the American Society of Clinical Oncology 2007, Part I. Vol 25, No. 18S (June 20 Supplement), abstract #5064

7/22/08